Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, has announced its participation in the Wells Fargo Healthcare Conference in Boston, MA from September 4-6, 2024. The company's management will engage in a fireside chat on Thursday, September 5, 2024, at 1:30pm EDT.
Mineralys focuses on developing medicines for hypertension, chronic kidney disease (CKD), and other aldosterone-related disorders. Investors and interested parties can access a live webcast of the fireside chat through the company's website under the 'News and Events' section of Investor Relations. A replay will be available for approximately 90 days after the event.
Mineralys Therapeutics (NASDAQ: MLYS), una compagnia biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla Wells Fargo Healthcare Conference a Boston, MA, dal 4 al 6 settembre 2024. La direzione dell'azienda parteciperà a un fireside chat giovedì 5 settembre 2024, alle 13:30 EDT.
Mineralys si concentra sullo sviluppo di medicinali per l'ipertensione, la malattia renale cronica (CKD) e altri disturbi correlati all'aldosterone. Gli investitori e le parti interessate possono accedere a una trasmissione web in diretta del fireside chat attraverso il sito web dell'azienda nella sezione 'Notizie ed Eventi' della Relazioni con gli Investitori. Una registrazione sarà disponibile per circa 90 giorni dopo l'evento.
Mineralys Therapeutics (NASDAQ: MLYS), una compañía biofarmacéutica en etapa clínica, ha anunciado su participación en la Wells Fargo Healthcare Conference en Boston, MA, del 4 al 6 de septiembre de 2024. La dirección de la compañía participará en un fireside chat el jueves 5 de septiembre de 2024, a la 1:30 p.m. EDT.
Mineralys se enfoca en el desarrollo de medicamentos para la hipertensión, la enfermedad renal crónica (CKD) y otros trastornos relacionados con la aldosterona. Los inversores y partes interesadas pueden acceder a una transmisión en vivo del fireside chat a través del sitio web de la empresa en la sección 'Noticias y Eventos' de Relaciones con Inversores. Una repetición estará disponible durante aproximadamente 90 días después del evento.
Mineralys Therapeutics (NASDAQ: MLYS)는 임상 단계의 생명공학 회사로, 2024년 9월 4일부터 6일까지 MA주 보스턴에서 열리는 웰스 파고 건강 회의에 참가한다고 발표했습니다. 회사 경영진은 2024년 9월 5일 목요일 오후 1시 30분 EDT에 파이어사이드 챗에 참여할 예정입니다.
Mineralys는 고혈압, 만성 신장 질환(CKD), 및 기타 알도스테론 관련 질환에 대한 약물을 개발하는 데 주력하고 있습니다. 투자자 및 관심 있는 모든 분들은 회사의 웹사이트 '투자자 관계' 섹션의 '뉴스 및 이벤트'에서 파이어사이드 챗의 라이브 웹캐스트를 시청할 수 있습니다. 이벤트 후 약 90일 동안 다시보기도 제공될 예정입니다.
Mineralys Therapeutics (NASDAQ: MLYS), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la Wells Fargo Healthcare Conference à Boston, MA, du 4 au 6 septembre 2024. La direction de l'entreprise participera à un fireside chat le jeudi 5 septembre 2024 à 13h30 EDT.
Mineralys se concentre sur le développement de médicaments pour l'hypertension, la maladie rénale chronique (CKD) et d'autres troubles liés à l'aldostérone. Les investisseurs et parties intéressées peuvent accéder à un webinaire en direct du fireside chat via le site de l'entreprise dans la section 'Actualités et Événements' des Relations Investisseurs. Une rediffusion sera disponible pendant environ 90 jours après l'événement.
Mineralys Therapeutics (NASDAQ: MLYS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der Wells Fargo Healthcare Conference in Boston, MA, vom 4. bis 6. September 2024 angekündigt. Die Unternehmensleitung wird am Donnerstag, den 5. September 2024, um 13:30 Uhr EDT an einem Fireside Chat teilnehmen.
Mineralys konzentriert sich auf die Entwicklung von Medikamenten für Bluthochdruck, chronische Nierenerkrankung (CKD) und andere mit Aldosteron verbundene Erkrankungen. Investoren und Interessierte können über die Unternehmenswebsite im Abschnitt 'News und Veranstaltungen' der Investor Relations auf einen Live-Webcast des Fireside Chats zugreifen. Eine Wiederholung wird etwa 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
RADNOR, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Wells Fargo Healthcare Conference, being held in Boston, MA on September 4-6, 2024.
| Wells Fargo Healthcare Conference | |
| Date: Time: Format: Webcast Link | Thursday, September 5, 2024 1:30pm EDT Fireside Chat |
A live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the fireside chat will be available on the Company’s website for approximately 90 days.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When is Mineralys Therapeutics (MLYS) participating in the Wells Fargo Healthcare Conference?
What format will Mineralys Therapeutics' (MLYS) presentation take at the Wells Fargo Healthcare Conference?
How can investors access Mineralys Therapeutics' (MLYS) presentation at the Wells Fargo Healthcare Conference?
What medical conditions does Mineralys Therapeutics (MLYS) focus on in its drug development?
